Screener
Organon OGN Jada — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
| ($ in millions) | Three Months Ended March 31, 2025 / U.S. | 2025 / Int’l | Total | U.S. | Int’l | Total |
|---|---|---|---|---|---|---|
| NuvaRing | 6 | 18 | 24 | 6 | 16 | 22 |
| Ganirelix Acetate Injection | 2 | 24 | 26 | 5 | 23 | 27 |
| Marvelon/Mercilon | — | 26 | 26 | — | 39 | 39 |
| Jada | 5 | — | 5 | 15 | — | 15 |
| Other Women’s Health (1) | 17 | 30 | 46 | 15 | 27 | 43 |
| General Medicines | ||||||
| Biosimilars | ||||||
| Renflexis | 42 | 15 | 57 | 44 | 12 | 57 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Organon's jada — revenue?
- Organon (OGN) reported jada — revenue of $5M in Q1 2026.
- How has Organon's jada — revenue changed year-over-year?
- Organon's jada — revenue decreased by 66.7% year-over-year, from $15M to $5M.
- What is the long-term trend for Organon's jada — revenue?
- Over 3 years (2021 to 2025), Organon's jada — revenue has grown at a 189.8% compound annual growth rate (CAGR), from $3M to $73M.
- What does jada — revenue mean?
- This metric represents the total gross sales generated by the Jada product line within the women's health portfolio. It serves as a key indicator of market adoption and commercial traction for this specific therapeutic solution. Tracking this revenue stream allows investors to evaluate the growth trajectory and contribution of this asset to the company's overall women's health segment performance.
Ask your AI about Organon's jada — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude